However, the genome-editing technique used in human cardiovascular disease therapy is still debatable due to the safety concern and ethical issues; hence, the pharmacological intervention on IL-6/gp130/STAT3 signal by raloxifene is more translatable compared with genome manipulation. The gene discussed is STAT3; the disease is cardiovascular disorder.